Galactomannan synergistic immune regulation type prebiotic syrup

Abstract

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

Description

Technical Field

[0001] This invention relates to the field of functional food technology, specifically to an immunomodulatory prebiotic syrup with galactomannan synergy. Background Technology

[0002] With the increasing awareness of health among the public, "intestinal health" and "immune regulation" have become core demands for functional foods. Prebiotics, as a "nutrient source" for gut probiotics, are widely used in the health industry due to their advantages such as being natural, safe, and without side effects. Among them, galactomannan (natural fructan) and galactomannan (GOS) are two prebiotics recognized by authoritative organizations such as the FDA and EFSA. They work by promoting the proliferation of lactic acid bacteria and bifidobacteria, respectively.

[0003] Existing prebiotic compound products have three major limitations: The synergistic mechanism only extends to the level of "microbial proliferation" and does not involve molecular pathways of immune regulation; High-concentration solutions are prone to crystallization and stratification due to imbalance of intermolecular forces; 3. Lack of functional enhancement: The direct regulatory effect of prebiotics on immune cells (such as macrophages and T cells) is relatively weak, and there is a lack of targeted synergistic combination with prebiotics. It is necessary to combine them with functional ingredients to enhance the effect. Summary of the Invention

[0004] The purpose of this invention is to provide an immunomodulatory prebiotic syrup with galactomannan synergy to solve the problems mentioned in the background art.

[0005] To achieve the above objectives, the present invention provides the following technical solution: A galactomannan-synergistic immunomodulatory prebiotic syrup, the active ingredients of which are composed of the following raw materials in weight percentage: fructooligosaccharides 20%-35%, galacto-oligosaccharides 10%-18%, stachyose 8%-15%, xylooligosaccharides 3%-7%, lactitol 5%-12%, galactomannan 5%-10%, yeast β-glucan 2%-5%, and N-acetylglucosamine 1%-3%; and the composition further comprises inulin and resistant dextrin as matrix filler and sustained-release carrier, wherein the content of inulin is 4%-8% and the content of resistant dextrin is 3%-6%, and the sum of the weight percentages of all active ingredients and carriers is 100%.

[0006] As a further preferred embodiment of the present invention, the preferred weight ratio range of the active ingredients is as follows: fructooligosaccharides 25%-30%, galactooligosaccharides 12%-15%, stachyose 9%-12%, xylooligosaccharides 4%-6%, lactitol 7%-10%, galactomannan 6%-8%, yeast β-glucan 3%-4%, N-acetylglucosamine 1.5%-2.5%, inulin 5%-7%, and resistant dextrin 4%-5%.

[0007] As a further preferred embodiment of the present invention, the optimal weight ratio of the active ingredients is as follows: fructooligosaccharides 28%, galactooligosaccharides 12%, stachyose 10%, xylooligosaccharides 5%, lactitol 8%, galactomannan 7%, yeast β-glucan 3.5%, N-acetylglucosamine 2%, inulin 6%, and resistant dextrin 4.5%.

[0008] As a further preferred embodiment of the present invention, it further comprises one or more probiotic freeze-dried powders selected from the genera *Lactobacillus* and *Bifidobacterium*, wherein the *Lactobacillus* genus is preferably *Lactobacillus rhamnosus* or *Lactobacillus paracasei*, and the *Bifidobacterium* genus is preferably *Bifidobacterium animalis* or *Bifidobacterium lactis*.

[0009] As a further preferred embodiment of the present invention: the probiotic freeze-dried powder is processed by multilayer microcapsule encapsulation technology, and its encapsulation wall material is composed of sodium alginate, chitosan and pectin in a specific ratio. This treatment can effectively resist gastric acid erosion and ensure the targeted colonization and release of probiotics in the intestine.

[0010] As a further preferred embodiment of the invention, it also includes a food-grade acceptable excipient system comprising natural high-intensity sweeteners such as steviol glycosides or mogrosides for adjusting sweetness, natural fruit concentrates or natural flavorings for improving flavor, pH adjusters such as citric acid or sodium citrate for stabilizing system acidity, and natural preservatives such as natamycin or ε-polylysine hydrochloride for extending shelf life.

[0011] A method for preparing a galactomannan-synergistic immunomodulatory prebiotic syrup, characterized by comprising the following steps: S1: Pretreatment and dissolution: Heat the specified amount of purified water to 55-65℃, and under constant temperature and continuous stirring conditions, slowly add fructooligosaccharides, galactooligosaccharides, stachyose, lactitol, inulin and resistant dextrin in sequence, ensuring that each component is completely dissolved before adding the next one, to obtain a uniform basic syrup solution. S2: Addition of functional ingredients: Cool the base syrup obtained in step S1 to below 40°C, and then add galactomannan, yeast β-glucan and N-acetylglucosamine in sequence, stirring gently until completely dispersed and dissolved; S3: Additive blending and homogenization: Add the pre-dissolved acidulant, sweetener and flavoring agent solution to the mixture obtained in step S2, stir evenly, and then homogenize the entire mixture through a high-pressure homogenizer at a pressure of 15-25MPa to ensure the system is stable and uniform. S4: Post-processing and filling: Cool the homogenized syrup to 20-25℃. If the formula contains probiotics, slowly mix in the microencapsulated lyophilized probiotic powder under aseptic conditions. Finally, perform aseptic filtration, filling and sealing.

[0012] Compared with the prior art, the beneficial effects of the present invention are: This invention constructs a multi-level, multi-target synergistic system through the combination of multiple components, surpassing the single dimension of traditional prebiotics that only focus on the proliferation of gut microbiota. In the formula, the combination of prebiotics with different degrees of polymerization and structures, such as fructose-based, galactose-based, and xylose-based, achieves precise nourishment and full coverage of different segments and different microbiota in the gut, forming a fast-slow energy supply mode that both rapidly optimizes the microbiota structure and maintains long-term homeostasis. Moreover, yeast β-glucan and N-acetylglucosamine extend the action from the microecology to the immune system and physical barrier. β-glucan can directly activate intestinal immune cells, while N-acetylglucosamine is a key raw material for repairing damaged intestinal mucosa. The three, together with the short-chain fatty acids produced by prebiotic metabolism, form a highly efficient regulatory loop integrating bacterial growth, membrane repair, and immunity. In addition, the addition of inulin and resistant dextrin not only serves as a filler carrier but also effectively improves the physical stability of the syrup by adjusting the osmotic pressure and viscosity of the system, preventing stratification or crystallization during storage and ensuring consistent product quality and taste. Attached Figure Description

[0013] Figure 1 This is a graph showing experimental data on intestinal absorption under different formulations according to the present invention. Detailed Implementation

[0014] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0015] Example 1, such as Figure 1 As shown: A galactomannan-synergistic immunomodulatory prebiotic syrup, the active ingredients of which are composed of the following raw materials in weight percentage: fructooligosaccharides 20%-35%, galacto-oligosaccharides 10%-18%, stachyose 8%-15%, xylooligosaccharides 3%-7%, lactitol 5%-12%, galactomannan 5%-10%, yeast β-glucan 2%-5%, and N-acetylglucosamine 1%-3%; and the composition further comprises inulin and resistant dextrin as matrix filler and sustained-release carrier, wherein the content of inulin is 4%-8% and the content of resistant dextrin is 3%-6%, and the sum of the weight percentages of all active ingredients and carriers is 100%.

[0016] As a further preferred embodiment of the present invention, the preferred weight ratio range of the active ingredients is as follows: fructooligosaccharides 25%-30%, galactooligosaccharides 12%-15%, stachyose 9%-12%, xylooligosaccharides 4%-6%, lactitol 7%-10%, galactomannan 6%-8%, yeast β-glucan 3%-4%, N-acetylglucosamine 1.5%-2.5%, inulin 5%-7%, and resistant dextrin 4%-5%.

[0017] As a further preferred embodiment of the present invention, the optimal weight ratio of the active ingredients is as follows: fructooligosaccharides 28%, galactooligosaccharides 12%, stachyose 10%, xylooligosaccharides 5%, lactitol 8%, galactomannan 7%, yeast β-glucan 3.5%, N-acetylglucosamine 2%, inulin 6%, and resistant dextrin 4.5%.

[0018] As a further preferred embodiment of the present invention, it further comprises one or more probiotic freeze-dried powders selected from the genera *Lactobacillus* and *Bifidobacterium*, wherein the *Lactobacillus* genus is preferably *Lactobacillus rhamnosus* or *Lactobacillus paracasei*, and the *Bifidobacterium* genus is preferably *Bifidobacterium animalis* or *Bifidobacterium lactis*.

[0019] As a further preferred embodiment of the present invention: the probiotic freeze-dried powder is processed by multilayer microcapsule encapsulation technology, and its encapsulation wall material is composed of sodium alginate, chitosan and pectin in a specific ratio. This treatment can effectively resist gastric acid erosion and ensure the targeted colonization and release of probiotics in the intestine.

[0020] As a further preferred embodiment of the invention, it also includes a food-grade acceptable excipient system comprising natural high-intensity sweeteners such as steviol glycosides or mogrosides for adjusting sweetness, natural fruit concentrates or natural flavorings for improving flavor, pH adjusters such as citric acid or sodium citrate for stabilizing system acidity, and natural preservatives such as natamycin or ε-polylysine hydrochloride for extending shelf life.

[0021] A method for preparing a galactomannan-synergistic immunomodulatory prebiotic syrup, characterized by comprising the following steps: S1: Pretreatment and dissolution: Heat the specified amount of purified water to 55-65℃, and under constant temperature and continuous stirring conditions, slowly add fructooligosaccharides, galactooligosaccharides, stachyose, lactitol, inulin and resistant dextrin in sequence, ensuring that each component is completely dissolved before adding the next one, to obtain a uniform basic syrup solution. S2: Addition of functional ingredients: Cool the base syrup obtained in step S1 to below 40°C, and then add galactomannan, yeast β-glucan and N-acetylglucosamine in sequence, stirring gently until completely dispersed and dissolved; S3: Additive blending and homogenization: Add the pre-dissolved acidulant, sweetener and flavoring agent solution to the mixture obtained in step S2, stir evenly, and then homogenize the entire mixture through a high-pressure homogenizer at a pressure of 15-25MPa to ensure the system is stable and uniform. S4: Post-processing and filling: Cool the homogenized syrup to 20-25℃. If the formula contains probiotics, slowly mix in the microencapsulated lyophilized probiotic powder under aseptic conditions. Finally, perform aseptic filtration, filling and sealing.

[0022] The core value of this invention lies in the fact that it is not simply a mixture of various functional ingredients, but rather the construction of a scientific, precise, multi-target synergistic system. This system breaks through the traditional prebiotic product's single-dimensional focus on promoting probiotic proliferation, deeply integrating three key aspects: microecological regulation, intestinal physical barrier repair, and direct activation of the immune system, forming a powerful three-in-one effect. Traditional products have vague functional pathways, while this formula, through clear component division of labor, achieves coherent regulation from the gut to the whole-body immune system. High-concentration syrups are prone to precipitation and stratification; this solution, through the scientific selection of the matrix carrier and process control, ensures the product's stability and uniformity throughout its shelf life. While simple prebiotics have a slow onset of action and a limited effect ceiling, this solution, by introducing immune activators and mucosal repair agents, significantly amplifies the final health benefits. This syrup can be used as a basic functional ingredient or end product, widely applied in dietary supplements, special medical purpose formula foods, functional beverages, and nutritional foods for infants and the elderly, precisely meeting modern consumers' core demands for gut health and immunity.

[0023] This module consists of fructooligosaccharides, galactooligosaccharides, stachyose, xylooligosaccharides, lactitol, galactomannan, inulin, and resistant dextrin. Their role extends far beyond providing a carbon source; they form a sophisticated feeding network. Fructooligosaccharides, galactooligosaccharides, and stachyose are fast-fermenting prebiotics, rapidly utilized by probiotics such as Bifidobacteria and Lactobacillus in the anterior colon to produce short-chain fatty acids, such as acetic acid and propionic acid. This quickly lowers the intestinal pH, inhibits harmful bacteria colonization, and creates a favorable acidic environment. Meanwhile, slow-fermenting prebiotics such as galactomannan and inulin, with their complex molecular structures and slow fermentation rates, can travel to the middle and posterior colon, providing sustained fuel for probiotics there, particularly promoting the growth of butyric acid-producing bacteria. This combination of fast and slow fermentation strategies ensures that probiotics throughout the entire colon are effectively nourished, avoiding nutritional blind spots. Different prebiotics exhibit different selectivity for bacterial strains. Xylooligosaccharides are hailed as super prebiotics, exhibiting extremely high selectivity for Bifidobacteria, achieving efficient proliferation with very low dosages. Stachyose is highly effective against certain specific Lactobacillus strains. Combining them can cover a broader spectrum of probiotics, achieving diversified optimization of the gut microbiota structure and avoiding new imbalances caused by the overgrowth of a single strain. The addition of lactitol not only provides sweetness, but its fermentation properties also help increase the water-holding capacity of intestinal contents, softening stool.

[0024] Short-chain fatty acids produced after prebiotics are fermented are key to their health benefits. Acetic acid can enter the bloodstream and affect systemic metabolism, propionic acid mainly acts on the liver and participates in the regulation of glucose and lipid metabolism, while butyric acid is the preferred energy source for colonic epithelial cells and is essential for maintaining the integrity of the intestinal barrier.

[0025] Yeast beta-glucan is a well-known biological response modifier. It can be specifically recognized by pattern recognition receptors, such as Dectin-1, on the surface of intestinal mucosal immune cells, such as macrophages and dendritic cells. This recognition activates a series of intracellular signaling pathways, leading to enhanced macrophage phagocytosis, increased reactive oxygen species production, and promotion of cytokine secretion. This trains and awakens the innate immune system, improving the body's vigilance and clearance of pathogens. This is a direct and rapid immune stimulus, perfectly complementing the indirect and slow immune effects of prebiotics through changes in gut microbiota. The intestinal mucosal barrier is the first line of defense against harmful substances entering the bloodstream. Its surface mucus layer is mainly composed of mucin, a highly glycosylated protein. N-acetylglucosamine is an important precursor for the synthesis of mucin glycans. Supplementing with NAG is equivalent to providing the building materials for repairing the intestinal mucosa. Clinical studies have shown that NAG supplementation can promote the synthesis and secretion of mucin, thicken the mucus layer, enhance its integrity, effectively reduce intestinal leakage, and prevent endotoxins, undigested food macromolecules, and other substances from entering the bloodstream and causing systemic low-grade inflammation. NAG is also a monomer of chitosan and possesses certain immunomodulatory activity, gently regulating the activity of immune cells. The synergistic effect of these three components leads to prebiotics promoting probiotic proliferation and producing a large number of SCFAs. SCFAs provide energy for intestinal epithelial cells and assist NAG in membrane repair. Simultaneously, the acidic environment created by SCFAs inhibits pathogens. A complete mucosal barrier provides a better colonization environment for probiotics and ensures that yeast β-glucan can be effectively recognized by submucosal immune cells, rather than directly entering the bloodstream. Immune cells activated by β-glucan further clear away any remaining pathogens that breach the physical barrier, maintaining intestinal immune homeostasis. These three interconnected steps form a powerful positive cycle, jointly constructing a robust defense line for intestinal health.

[0026] Inulin and resistant dextrin play crucial roles in this formula not only as prebiotics but also as stabilizers and carriers. High-concentration syrups have high osmotic pressure, which can easily lead to water activity imbalance, causing crystallization or microbial growth. As soluble dietary fibers, inulin and resistant dextrin effectively thicken the mixture, forming a stable colloidal system and preventing other components from settling or separating. They balance the osmotic pressure of the entire system, improving the product's physical stability. As dietary fibers, they are also prebiotics themselves; their slow fermentation properties result in a more gradual release of nutrients, helping to maintain a stable energy supply for the gut microbiota.

[0027] Stage S1: Staged temperature-controlled dissolution. Easily soluble sugars are first dissolved at 55-65℃. This temperature accelerates dissolution while avoiding excessive Maillard reactions that could alter color or flavor. Inulin and resistant dextrin are added at this stage to utilize their hydration properties, forming a stable network structure in advance and providing a uniform matrix for subsequent components. Stage S2: Low-temperature addition of functional ingredients. The system is cooled to below 40℃ before adding galactomannan, yeast β-glucan, and NAG because these components are relatively heat-sensitive. High temperatures may damage the higher-order structure of β-glucan, affecting its immunomodulatory activity; they may also cause unnecessary reactions in NAG. Low-temperature addition maximizes the protection of their functional activity. Stage S3: High-pressure homogenization. This is a crucial step in ensuring product shelf-life stability. Homogenization breaks down any potential sugar microcrystals and fat globules, resulting in a uniform particle size and distribution throughout the system, effectively preventing stratification, precipitation, and oil separation during storage. Stage S4: Post-processing to ensure probiotic activity. Probiotics are extremely sensitive to heat, acid, and oxygen. Adding them as a final step under low-temperature, sterile conditions, and employing microencapsulation technology creates multiple layers of protection. The microcapsule wall material effectively resists stomach acid, ensuring more live bacteria are delivered directly to the intestines for colonization, significantly improving the product's efficacy. For individuals with weakened immune systems, the product works synergistically to rapidly and continuously enhance innate and adaptive immunity, reducing the risk of infection. For those with intestinal dysfunction, such as patients with irritable bowel syndrome (IBS), prebiotics help correct gut microbiota imbalance, SCFAs and NAG soothe the intestines, repair the mucosa, and alleviate discomfort such as bloating and abdominal pain. The immunomodulatory effects of β-glucan also help improve low-grade inflammation associated with IBS. Antibiotics can severely disrupt the balance of gut microbiota. Supplementing with this product during or after antibiotic use rapidly provides nutrients to surviving beneficial bacteria, promotes gut microbiota recovery, competitively inhibits pathogenic bacteria such as Clostridium difficile, and effectively prevents or reduces diarrhea. For modern urban dwellers with irregular eating habits and high stress levels, this product can help maintain the balance of the gut microbiota, strengthen the intestinal barrier, and improve overall health.

[0028] This invention, through its ingenious formulation design and scientific preparation process, successfully links the three cornerstones of health: gut microbiota, mucosal barrier, and immune system. It is not merely a prebiotic supplement, but a highly effective gut health manager. Through multi-target and multi-level synergistic effects, it provides consumers with a comprehensive, stable, and efficient solution for gut and immune health, representing an important direction for future functional food research and development.

[0029] It should be noted that the above embodiments are only specific and clear descriptions of the technical solutions and features of this application. Solutions or features that are prior art or common knowledge to those skilled in the art will not be described in detail in the above embodiments.

[0030] Furthermore, the technical solutions of this application are not limited to the above embodiments. Those skilled in the art should consider the specification as a whole, and the technical solutions in each embodiment can also be appropriately combined to form other implementation methods that can be understood by those skilled in the art.

Claims

1. A galactomannan-synergistic immunomodulatory prebiotic syrup, characterized in that, Its active ingredients are composed of the following raw materials in weight percentage: fructooligosaccharides 20%-35%, galactooligosaccharides 10%-18%, stachyose 8%-15%, xylooligosaccharides 3%-7%, lactitol 5%-12%, galactomannan 5%-10%, yeast β-glucan 2%-5%, and N-acetylglucosamine 1%-3%; and the composition further includes inulin and resistant dextrin as matrix fillers and sustained-release carriers, wherein the content of inulin is 4%-8%, the content of resistant dextrin is 3%-6%, and the sum of the weight percentages of all active ingredients and carriers is 100%.

2. The galactomannan-synergistic immunomodulatory prebiotic syrup according to claim 1, characterized in that, The preferred weight ratio range of the active ingredients is as follows: fructooligosaccharides 25%-30%, galactooligosaccharides 12%-15%, stachyose 9%-12%, xylooligosaccharides 4%-6%, lactitol 7%-10%, galactomannan 6%-8%, yeast β-glucan 3%-4%, N-acetylglucosamine 1.5%-2.5%, inulin 5%-7%, and resistant dextrin 4%-5%.

3. The galactomannan-synergistic immunomodulatory prebiotic syrup according to claim 2, characterized in that, The optimal weight ratio of the active ingredients is as follows: 28% fructooligosaccharides, 12% galactooligosaccharides, 10% stachyose, 5% xylooligosaccharides, 8% lactitol, 7% galactomannan, 3.5% yeast β-glucan, 2% N-acetylglucosamine, 6% inulin, and 4.5% resistant dextrin.

4. A galactomannan-synergistic immunomodulatory prebiotic syrup according to any one of claims 1 to 3, characterized in that, It also contains one or more freeze-dried probiotic powders selected from the genera *Lactobacillus* and *Bifidobacterium*, wherein the *Lactobacillus* genus is preferably *Lactobacillus rhamnosus* or *Lactobacillus paracasei*, and the *Bifidobacterium* genus is preferably *Bifidobacterium animalis* or *Bifidobacterium lactis*.

5. The galactomannan-synergistic immunomodulatory prebiotic syrup according to claim 4, characterized in that, The probiotic freeze-dried powder is processed using multi-layer microencapsulation technology. The encapsulation wall material is composed of sodium alginate, chitosan, and pectin in a specific ratio. This process can effectively resist gastric acid erosion and ensure the targeted colonization and release of probiotics in the intestine.

6. A galactomannan-synergistic immunomodulatory prebiotic syrup according to any one of claims 1 to 3, characterized in that, It also includes a food science-acceptable excipient system, which includes natural high-intensity sweeteners such as steviol glycosides or mogrosides for adjusting sweetness, natural fruit concentrates or natural flavorings for improving flavor, pH adjusters such as citric acid or sodium citrate for stabilizing system acidity, and natural preservatives such as natamycin or ε-polylysine hydrochloride for extending shelf life.

7. A method for preparing an immunomodulatory prebiotic syrup synergistic with galactomannan as described in any one of claims 1 to 6, characterized in that, The method includes the following steps: S1: Pretreatment and dissolution: Heat the specified amount of purified water to 55-65℃, and under constant temperature and continuous stirring conditions, slowly add fructooligosaccharides, galactooligosaccharides, stachyose, lactitol, inulin and resistant dextrin in sequence, ensuring that each component is completely dissolved before adding the next one, to obtain a uniform basic syrup solution. S2: Addition of functional ingredients: Cool the base syrup obtained in step S1 to below 40°C, and then add galactomannan, yeast β-glucan and N-acetylglucosamine in sequence, stirring gently until completely dispersed and dissolved; S3: Additive blending and homogenization: Add the pre-dissolved acidulant, sweetener and flavoring agent solution to the mixture obtained in step S2, stir evenly, and then homogenize the entire mixture through a high-pressure homogenizer at a pressure of 15-25MPa to ensure the system is stable and uniform. S4: Post-processing and filling: Cool the homogenized syrup to 20-25℃. If the formula contains probiotics, slowly mix in the microencapsulated lyophilized probiotic powder under aseptic conditions. Finally, perform aseptic filtration, filling and sealing.

Images